Biocaptiva Ltd, an Edinburgh, Scotland-based company developing a cell-free DNA (cfDNA) capture device designed to transform liquid biopsy testing for cancer management, raised £2.1m in additional seed funding.
The round was led by existing investor Archangels, which was joined by Scottish Enterprise and Cancer Research Horizon, and new investor Old College Capital.
The investment will be used to fund the company through the first in human trials with the BioCaptis, expected to generate its first data before the end of 2022, and to prepare for regulatory trials which are planned to start in 2023.
Led by Jeremy Wheeler, CEO, Biocaptiva is developing the BioCaptis, a medical device which has the potential to transform liquid biopsy testing for cancer management, by improving early diagnosis and monitoring of disease and enhancing clinical trial data of cancer patients.
The BioCaptis captures up to 100x more cell free DNA (cfDNA) than a venous blood draw, yielding cfDNA in high quality and quantity for testing, addressing the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients.